PubMed · 2012 · 43 citations · 0 references
MedicineInternal MedicineDiabetologyEarly DetectionGood Laboratory PracticeBlood Glucose MonitoringDiabetes ControlDiabetes ManagementDiabetes MellitusGlycemic ControlGlycemic MonitoringDiabetes DiagnosisDiabetes ScreeningGlycated Hemoglobin MonitoringGlycemic TargetsImpaired Glucose Tolerance
In New Zealand laboratories the measurement of glycated haemoglobin (HbA1c) for diagnosis of diabetes is now only reported in SI units of mmol/mol. HbA1c is now recommended as the preferred test to diagnose diabetes in most circumstances. The requirement for a second positive test in asymptomatic individuals is retained. An HbA1c greater than and equal to 50 mmol/mol (repeated on a second occasion in asymptomatic patients) is diagnostic of diabetes and a value less than and equal to 40 mmol/mol represents normal glucose tolerance. For patients with an initial HbA1c result of 41-49 mmol/mol, cardiovascular risk assessment and lifestyle interventions are recommended with repeat HbA1c screening in 6-12 months. For patients whose HbA1c is less than and equal to 40 mmol/mol, repeat screening (including for CVD risk) at intermittent intervals is recommended as per published guidelines.